Monitor for any subsequent 13D filing by Apothecary Capital or Sebulsky personally — his background as a healthcare-focused portfolio manager could signal increased activist or strategic oversight. No immediate trading catalyst.
Price Chart
Executive Summary
MeiraGTx appointed Alan M. Sebulsky, a veteran healthcare portfolio manager with over 40 years of experience, to its Board of Directors effective September 23, 2026. The appointment adds significant biopharmaceutical investment and public company board expertise as the company transitions toward commercialization, but is a routine governance event with no immediate financial impact.
Key Facts
- Alan M. Sebulsky appointed to Board as Class I director, effective September 23, 2026, term expiring at 2028 annual meeting.
- Sebulsky served as Partner and Portfolio Manager at Adage Capital Management for 14 years, managing a biopharmaceutical portfolio with over $2 billion in assets.
- He reestablished Apothecary Capital LLC in April 2026 and serves as its Managing Member.
- Sebulsky currently serves on the board of Parabilis Medicines, Inc. and previously served on boards of Jazz Pharmaceuticals PLC and Arrow International, Inc.
- He will serve on the Science and Technology Committee.
- No related party transactions between the company and Sebulsky.
- No departure of any existing director or officer.
Financial Impact
No financial impact — board appointment with no compensation details beyond standard non-employee director compensation program.
Risk Factors
- No financial or operational data provided in the filing.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-109824 |
| Document: mgtx-20260922xex99d1.htm | 0001104659-26-109824 |
| Document: 0001104659-26-109824-index-headers.html | 0001104659-26-109824 |
| Document: 0001104659-26-109824-index.html | 0001104659-26-109824 |
| Document: 0001104659-26-109824.txt | 0001104659-26-109824 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 144 | $10.82 | awaiting T+60 | — | $9.18 (−15.16%) |
Sep 24, 2026 4w ago | 3 | $10.91 | awaiting T+60 | — | $9.18 (−15.86%) |
Sep 23, 2026 4w ago | 8-K | $11.75 | awaiting T+60 | — | $9.18 (−21.87%) |
Aug 18, 2026 9w ago | 144 | $14.97 | awaiting T+60 | — | $9.18 (−38.68%) |
Aug 13, 2026 10w ago | 8-K | $12.67 | awaiting T+60 | — | $9.18 (−27.55%) |
Aug 13, 2026 10w ago | Press Release | $12.67 | awaiting T+60 | — | $9.18 (−27.55%) |
Jul 7, 2026 15w ago | 8-K | $14.66 $11.00 | ▼ −24.97% | ▼ −26.96% | $9.18 (−37.38%) |
May 19, 2026 22w ago | 144 | $9.58 $13.52 | ▲ +41.13% | ▲ +36.12% | $9.18 (−4.18%) |
May 14, 2026 23w ago | 8-K | $9.95 $13.02 | ▲ +30.85% | ▲ +27.27% | $9.18 (−7.74%) |
May 14, 2026 23w ago | Press Release | $9.95 $13.02 | ▲ +30.85% | ▲ +27.27% | $9.18 (−7.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers